Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease
The Advisory Committee on Immunization Practices (ACIP) recommends using the immunization record and not serologic testing to determine immunity against measles and rubella in the general population, due to potential false negatives. However, it is unknown whether the immune response is less durable among patients who are immunosuppressed.
The primary aim of this study was to evaluate sustained vaccine-induced measles, mumps, and rubella (MMR) antibody concentrations in immunosuppressed patients with inflammatory bowel disease (IBD).
We performed a cross-sectional study to compare antibody concentrations following the two-dose (MMR) vaccine among 46 patients with IBD and 20 healthy controls (HC). Three IBD groups stratified by the immunosuppressive regimen that preceded study entry for at least 3 months: (1) thiopurine monotherapy, (2) anti-TNF monotherapy, or (3) combination therapy (anti-TNF agent combined with an immunomodulator) were enrolled.
All subjects had measurable antibody concentrations to the three vaccine viruses. Age and time since receipt of MMR series were similar in both groups. There were no difference in the antibody concentration of measles (IBD 667 mIU/ml vs HC 744 mIU/ml; p = 0.45), mumps (IBD 339 EU/ml vs HC 402 EU/ml; p = 0.62), or rubella (IBD 25 mIU/ml vs HC 62 mIU/ml; p = 0.11) among the groups. No differences in antibody concentrations were found among the IBD treatment groups.
Immunosuppressed patients with IBD have sustained antibody concentrations comparable to healthy controls. Thus, gastroenterologist should follow the ACIP recommendations and use the immunization record when available to determine immunity to measles and rubella in patients with IBD.
Clinical Trials Registry # NCT02434133.
KeywordsImmunization Measles Mumps Rubella Inflammatory bowel disease Immunity
This work was supported by Judy L. and Sal A. Troia, University of Wisconsin Division of Gastroenterology and Hepatology and the University of Wisconsin School of Pharmacy.
Compliance with ethical standards
Conflict of interest
Drs. Caldera, Misch, Wald, and Reichelderfer and Ms. McCrone, Ms. Garmoe, Mr. Megna, and Miss Ley declare that they have no competing interests/financial disclosures. Dr. Hayney served on the speakers’ bureau for Sanofi Pasteur Vaccines and an advisory board for GlaxoSmithKline Vaccines. Dr. Saha is a consultant with UCB Biosciences.
- 3.McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2013;62:1–33.Google Scholar
- 5.Fiebelkorn AP, Redd SB, Gastañaduy PA, et al. A comparison of post-elimination measles epidemiology in the United States, 2009–2014 versus 2001–2008. J Pediatr Infect Dis Soc. 2017;6:40–48.Google Scholar
- 13.Wisconsin Department of Health Services. Wisconsin Immunization Registry (WIR). https://www.dhs.wisconsin.gov/immunization/wir.htm. Accessed May 1, 2018.
- 18.Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:13–50.Google Scholar